Summary.-Serum inhibition of autochthonous lymphocyte cytotoxicity for tumour cells has been studied in 112 cases of colonic carcinoma. Addition of patient's serum to the lymphocyte tumour cell reaction mixture resulted in decreased cytotoxic reactivity of lymphocytes from 8 of 39 cytotoxic positive cases. It was also shown that sera could inhibit if separately preincubated with the lymphocytes (4 cases) or the target cells (2 cases). A tumour antigen preparation inhibited only when incubated with the lymphocytes. Inhibition by serum or antigen appeared to be specific for colon carcinoma. Four cases were specially studied to determine the mode of lymphocyte killing of tumour cells: in 3 it was mediated largely if not entirely by T lymphocytes, and in the fourth by both T and non-T cells. The findings support the view that T lymphocytes lose their anti -tumour reactivity in vivo in the presence of circulating antigen or antigen-antibody complexes such as would occur with progressive tumour growth. IN 
IN PREVIOUS reports of lymphocyte anergy in patients with carcinoma (Nind et al., 1973) , it was speculated that the observed in vitro inactivity of the local lymphocyte populations might be due to in vivo inactivation of specific effector cells by free tumour antigen or complexes of tumour antigen with tumour directed antibody. This would explain the decrease in leucocyte cytotoxicity and the increase in serum inhibitory effect that follows progressive growth or regrowth of tumour . Study of the phenomenon of inhibition of leucocyte cytotoxicity has hitherto been hampered by ignorance of the particular effector cell type when testing in vitro.
We have now obtained inhibition of cytotoxicity by pretreatment of effector or target cell populations with sera of colon carcinoma patients and have also prepared a tumour antigen extract capable of inactivating the effector cells. The reactions in limited cross-reactivity tests with other tumour systems appeared to be specific for colon carcinoma. Fractionation studies in 4 cases showed the lymphocyte class cytotoxic for the colonic carcinoma cells to be predominantly T cell.
MATERIALS AND METHODS
Specimen and blood collection were as described previously (Nairn et al., 1971; Nind et al., 1973) . Tumours, lymph nodes adjacent to the tumour, and in 2 cases spleen removed at operation, were teased gently into culture medium 199 containing 10% foetal calf serum (hereafter referred to as the culture medium). The resultant suspensions (tumour cells washed twice, spleen and lymph node cells washed 7 times with culture medium) were used fresh for immediate testing and any residue was stored with 10% dimethylsulphoxide in liquid nitrogen for later use. Lymphocytes were obtained from heparinized blood samples by sedimentation of the erythrocytes at 37°C and washing the leucocyte-rich supernatant plasma through a 2 cm glass wool column with culture medium. The lymphocyte eluate, which was contaminated by less than 10% granulocytes, was washed 7 times with culture medium before use.
Serum obtained from clotted blood samples from each patient was complement inactivated at 56°C for 30 min.
Lymphocyte cytotoxicity testing.-This was performed quantitatively in Falcon 3034 microtest plates by a modification of the method of Takasugi and Klein (1970) . Tumour cell suspensions, adjusted to 105 cells/ml in culture medium were micropipetted in 10 ,ul volumes into each well. Plates were incubated for 24 h at 37°C in a moist atmosphere of 5% CO2 in air. They were then washed 3 times with culture medium to remove non-adhered tumour cells. Those remaining in each well were counted and lymphocytes were added at a ratio of 200 to 1 tumour cell, in rows of 5 or 6 replicate wells for each experiment. The culture plate was reincubated for a further 48 h, washed gently 3 times with physiological saline at 37°C, and the remaining adherent cells were fixed with methanol for 10 min and counted under water using an inverted phase-contrast microscope. Test blood lymphocytes were accompanied by a row of homologous control blood lymphocytes obtained from 1 of 20 normal healthy adults of either sex. Control splenocytes were from a splenectomized patient who had a small leiomyosarcoma of the stomach. Cytotoxicity was expressed as nC -nT 100
where nC is the mean number of tumour cells remaining adherent in the control wells and nT the mean number remaining in the test wells. Student's t test was performed for each experiment and a difference between cytotoxicity means at the P < 0 05 level wras regarded as significant. Serum inhibition of lymphocyte cytotoxicity.-This was tested in 112 cases (39 of which were positive for autochthonous lymphocyte cytotoxicity by blood, lymph node or spleen) by the incorporation of 500 patient's serum in the lymphocyte suspension immediately before adding to the target cells. As controls, 500 normal group AB serum was added to patient's lymphocytes, and each serum was tested on homologous normal lymphocytes. Inhibition was expressed as a percentage according to the formula CAB -CP 100 CAB where CAB was the cytotoxicity of the patient's lymphocytes with normal group AB serum and Cp their cytotoxicity with the patient's serum. Student's t test was used to compare the cell counts with test and control sera and a difference between means at the P < 0-05 level was regarded as significant inhibition.
Preincubation of lymphocytes with serum.-Three sera (Cases 1, 2, 4) with strong autochthonous inhibition by the routine test were also tested in homologous colonic carcinoma/ lymphocyte systems (Cases 1, 3, 6, 32, 37) (see Table I ). One or 2 of these 3 sera were preincubated with the lymphocytes of each of the 5 cases before addition to target tumour cells. This was performed by adding to 5 ,ll of test serum in a polystyrene Durham tube, 0-1 ml of lymphocyte suspension, usually containing 2 x 10f6/ml, adjusted where necessary to provide the usual ratio of lymphocytes to tumour cells of 200: 1. After mixing, the tube was incubated at 37°C in a moist atmosphere of 5% CO2 in air for 45 min. The cells were then washed twice with culture medium by centrifugation at 500 gmax for 5 min and resuspended in 0-1 ml of culture medium; 10 ,ul aliquots were added to target cell wells for cytotoxicity testing in the usual way. Inhibition was detetmined using similar cont-rols and the same calculation procedure as for the routine serum inhibition test.
Specifiicity of serum inhibition.-Crossreactive inhibition tests by serum from colonic carcinoma patients were performed with cytotoxic lymphocytes and target cells from different colonic carcinomata, carcinomata of the stomach and malignant melanomata. By the routine technique, inhibitory sera from up to 3 colonic carcinomata were tested by addition to the lymphocyte tumour systems of 3 other homologous colonic carcinomata, 1 gastric carcinoma and 3 melanomata. Autochthonous inhibitory sera from 1 gastric carcinoma and 2 melanomata were examined in cytotoxicity tests of 2 autochthonous lymphocyte positive colonic carcinoma cases. The specificity of inhibitory sera preincubated with lymphocytes was examined for up to 3 colonic carcinoma sera tested with the lymphocytes of each of 5 homologous colonic carcinomata, 2 gastric carcinomata and 2 melanomata reacted against their autochthonous tumours.
A. NTND, N. MATTHEWS, E. PIHL, J. ROLLAND AND R. NAIRN Autochthonous inhibitory sera from 1 gastric carcinoma and 2 melanoma patients were preincubated with the lymphocytes of each of 3 colonic carcinoma cases and the lymphocytes then tested against their respective tumours.
Preincubation of lymphocytes with antigen. -Homogenized and de-fatted tissue from a colonic carcinoma (Case 1) was acid extracted by the method of Dickinson, Caspary and Field (1973) , dialysed against water and freeze-dried for use as required. A similar extract was prepared from 10 pooled normal colon mucosas. Any inhibitory, activity of the preparations was determined by preincubating at concentrations of 5, 5 x 10-1, 5 X 10-2, 5 x 10-3 and 5 x 10-4 /g dry weight of antigen per ml with the splenocytes from Case 1, which were then washed twice and tested for cytotoxicity by adding to Case 1 tumour cells in microculture plates. In control cytotoxicity experiments, equivalent concentrations of either antigen were preincubated with homologous normal lymphocytes or splenocytes. Specificity of inhibition by the tumour antigen was investigated by preincubating the extract at the same concentrations with lymphocytes from one case each of carcinoma of the stomach and melanoma before they were reacted with their respective tumour cells. In further experiments lymphocytes from 4 other colonic carcinoma cases, one other gastric carcinoma and one other melanoma were pretreated with 0 5 ,ug/ml of either antigen.
Preincubation of lymphocytes with antigen plus serum.-To determine if serum and antigen effects were additive, Case 1 serum, which inhibited 4 of 5 colonic carcinoma tests, was combined with 0 5 ,ug/ml of the tumour antigen extract, which gave alone about 50% inhibition. The mixture was preincubated with the lymphocytes of the same 5 cases, which were then tested for cytotoxicity against their respective targets and compared with lymphocytes pretreated with serum or tumour antigen alone.
Preincubation of target tumour cells with antigen and serum.-The tumour cells of 2 cases (Case 1, 6) were preincubated with tumour antigen, inhibitory serum or both together. Replicate tumour cell microcultures were incubated at 37°C for 45 min in a moist atmosphere of 5% CO2 in air with 0-01 ml aliquots of (a) 5% inhibitory serum.
(b) 0-5 ,tg/ml of tumour antigen or (c) a mixture of both, each at the same concentration as in (a) or (b). The preparations were then washed twice with culture medium and the relevant lymphocytes were added in the usual ratio of 200: 1 tumour cell. Comparison was made with tests against untreated target cells.
Fractionation of lymphocyte populations by rosette formation.-Human lymphocytes forming rosettes with sheep erythrocytes have the characteristics of T cells (Coombs et al., 1970; Jondal, Holm and Wigzell, 1972) . Lymphocyte preparations purified by Hypaque-Ficol sedimentation were incubated with sheep erythrocytes for 1 h at 37°C and again centrifuged in Hypaque-Ficol (Wybran et al., 1974) . The non-rosette forming cells at the interface and the rosetted cells in the pellet were collected carefully and counted. The cells were washed twice and resuspended in culture medium at the appropriate concentration for cytotoxicity testing (usually 2 x 106/ml). Sheep erythrocytes were added to the unfractionated and non-rosette forming populations to make the cell density the same as in the rosette forming fraction. Aliquots of either fraction and of the unfractionated cells were added to microcultures of target cells for cytotoxicity testing in a minimum of 10 replicate wells to give at least 18 degrees of freedom for each test of significance. In 2 experiments, normal homologous lymphocyte populations (one spleen, one blood) were fractionated simultaneously with the test lymphocytes to provide cytotoxicity controls. In another 3 experiments, where this was not done, the test preparation was compared with an unfractionated control. Preliminary experiments with normal blood lymphocytes showed that the fractionation did not confer cytotoxicity on non-cytotoxic unfractionated cells.
RESULTS

Serum inhibition of lymphocyte cytotoxicity
Eight of the 39 (21%) lymphocyte cytotoxic cases showed significant reduction of cytotoxicity by their serum added to the lymphocyte/tumour cell mixture (Table I) . Three of the inhibitory sera tested (Cases 1, 2, 4) produced significant inhibition with 3 other colonic carcinoma systems but only slight inhibition in 20±2  15±3  17±6  6±2  31±2  23±2  29±4  21±4  21±2  18±2  26±5  24±5   35±3  23±2   18±2   17±4  19±2  15±2  21±2  15±2  21±5  17±4  25±6  25±3  21±3  20±2  13±2  15±2  27±3  26±3  23±3  21±3  28±4  25±5  8±1   7±2   47±5  44±5  4±1  4±1  39±8  45±7   27±5  30±2  38±7  48±9  10±3  11±5  12±3  13±3  11±2  15±5   4±1  6±2   14±4  19±4  9±2  11±3  16±2  20±5  15±9  18±9  18±6  21±2  12±2  12±1  20±3  23±2   33±15  34±7   18±2  19±2  20±4  22±3  10±3  11±3  12±3 12±5 Case no. 5 /zg/ml 0 5 jig/ml 5 /pg/ml 0 5 ,g/ml of Case 1 0 5 (Cases 1, 32, 36) .
The results of preincubating with the mixture of antigen plus serum, summarized also in Table II , were not uniform in the 5 cases studied. Where preincubation with either the serum or antigen separately caused inhibition, in Case 37, the mixture gave increased inhibition while in Cases 1 and 32 there was no change. Where only antigen reduced cytotoxicity (Case 3), addition of the inhibitory sera abrogated this effect. There was no change in serum inhibition in Case 6 by adding tumour antigen.
Additional data from separate experiments (Table III) make comparisons between lymphocyt2 and target cell preincubations. The difference in the percentage cytotoxicity of similar preparations in Tables II and III The colonic carcinoma antigen preparation, as might be expected, had no effect on the tumour cells (Table III) . Inhibitory serum blocked tumour cells as targets whether tested against autochthonous or homologous lymphocytes. Combination of serum with the antigen preparation studied in Cases 1 and 6 resulted in abrogation of serum blocking. Serum abrogation of the in vitro cytotoxicity in our tests appears to be tumour determined because there was no cross-reaction with unlike carcinomata. The specificity of inhibitory tumour antigen is in contrast with the observations of Dickinson et al. (1973) ; they found with the macrophage electrophoretic mobility (MEM) test that antigen material prepared by the same method crossreacted with all tumour types. The difference may be attributable to the lymphocyte cytotoxicity being a functional effector test, possibly less sensitive but more specific than MEM, which is a reactor response perhaps capable of being provoked by a broader spectrum of antigens. The tumour type specificity does not support nonspecific explanations of inactivation in vivo. The apparent quantitative inhibition by antigen of the effector cells is consistent with the view that progressive growth of tumour, by increasing concentration of soluble tumour antigen in the circulation and acting either alone or complexed with antibody, can impair the effector responsiveness in vivo of anti-tumour lymphocytes.
